ProShares Ultra Nasdaq Biotechnology Rating $55.46 -2.07 (-3.60%) Closing price 03:55 PM EasternExtended Trading$55.48 +0.02 (+0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.70Holdings in BIB have an aggregate rating of Moderate Buy based on 346 analyst ratings issued in the past year covering 19 companies (36.9% of the portfolio).BIB Aggregate Price Target$55.46High Prediction$55.46Average Prediction$55.46Low Prediction$55.46Holdings in BIB have an aggregate price target of $55.46 and a range of $55.46 to $55.46 covering 19 companies (36.9% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 BIB Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.53%GILDGilead Sciences$110.99-2.4%4.9643 of 5 stars2.89$117.17 5.6%28Trending NewsAnalyst Revision4.22%AMGNAmgen$271.18-2.9%4.7775 of 5 stars2.30$309.15 14.0%20Positive NewsAnalyst Forecast3.94%VRTXVertex Pharmaceuticals$381.87+1.4%4.911 of 5 stars2.61$493.81 29.3%28Trending NewsAnalyst UpgradeAnalyst Revision3.86%REGNRegeneron Pharmaceuticals$555.51-3.7%4.7443 of 5 stars2.82$817.67 47.2%28Positive News3.36%ALNYAlnylam Pharmaceuticals$449.58-1.9%3.6114 of 5 stars2.86$439.58 -2.2%282.95%AZNAstraZeneca$73.53-2.4%3.165 of 5 stars2.75$86.00 17.0%4Positive News1.67%INSMInsmed$135.59-3.8%3.1854 of 5 stars2.94$139.86 3.1%17Positive News1.53%ARGXargenex$711.09-2.6%4.2025 of 5 stars3.08$789.20 11.0%24Analyst Upgrade1.35%BIIBBiogen$135.67-1.5%4.6464 of 5 stars2.35$182.04 34.2%31Trending NewsAnalyst Forecast1.16%UTHRUnited Therapeutics$425.42-3.0%4.515 of 5 stars2.69$438.85 3.2%13Positive NewsInsider Trade1.03%INCYIncyte$81.66-3.0%4.7601 of 5 stars2.33$83.67 2.5%18Analyst Forecast1.02%ILMNIllumina$92.19-2.4%4.8176 of 5 stars2.21$123.06 33.5%19Positive News0.95%RPRXRoyalty Pharma$34.90-2.4%4.8256 of 5 stars3.33$48.00 37.5%3Positive News0.92%TEMTempus AI$77.33-2.4%1.9321 of 5 stars2.54$70.17 -9.3%13Gap Up0.91%MEDPMedpace$487.95-1.9%4.1737 of 5 stars1.94$422.27 -13.5%17Analyst Downgrade0.90%SMMTSummit Therapeutics$20.26-1.2%3.1095 of 5 stars2.53$31.29 54.4%17Analyst Forecast0.89%NBIXNeurocrine Biosciences$140.89-3.9%4.5579 of 5 stars2.85$161.89 14.9%20Analyst Forecast0.88%ONCBeOne Medicines$328.71-0.3%1.8011 of 5 stars3.11$336.30 2.3%90.84%SNYSanofi$45.07-2.9%3.9911 of 5 stars3.11$62.67 39.0%9 This page (NASDAQ:BIB) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
